drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA/CEACAM5); administered intraperitoneally to mediate CAR signaling and cytotoxic killing of CEA-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor specific for CEA (CEACAM5). CAR engagement with CEA on tumor cells triggers CD3ΞΆ/co-stimulatory signaling, activating T-cell cytotoxicity and cytokine release to kill CEA-positive cancer cells. Administered intraperitoneally to target peritoneal tumor deposits.
drug_name
PTC13 (CEA-targeted CAR-T)
nct_id_drug_ref
NCT06821048